Concord Drugs Limited (BOM:538965)

Market Cap	901.17M +38.6%
Revenue (ttm)	860.69M +82.5%
Net Income	20.51M +380.8%
EPS	1.72 +305.7%
Shares Out	13.18M
PE Ratio	39.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,885
Open	73.97
Previous Close	71.69
Day's Range	66.30 - 73.97
52-Week Range	61.00 - 92.52
Beta	0.59
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Concord Drugs

Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products; ready-to-fill pellets and multiple unit pellets system; other drugs in the form of tablets, capsules, injectables such as small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. Concord Drugs Limited was incorporated in 1995 and is based in Hyderabad, India.

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 250
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 538965

Financial Performance

In fiscal year 2026, Concord Drugs's revenue was 787.37 million, an increase of 74.02% compared to the previous year's 452.45 million. Earnings were 10.55 million, an increase of 213.80%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 17, 2026

Data Sources Report a data error